It's Time to Move Forward

Prosigna Package Insert Prosigna Package Insert
 
Prosigna MSDS Prosigna MSDS

nCounter Hybridization Buffer

nCounter Prep Plate

nCounter Capture ProbeSet

nCounter Reporter CodeSet

nCounter Cartridge

Prosigna Product Data Sheet Prosigna Product Data Sheet
nCounter® User Manual nCounter® Dx Analysis System User Manual (MAN-C0034)
Roche FFPET Kit
Package Insert
1. Go to https://dialog1.roche.com/PI/us/eLabDoc
2. Enter REF number printed on the outside of the Roche kit box
3. Choose the newest version of Method Sheet and download
 

TransATAC Clinical Verification Study

Click here to access the TransATAC clinical verification study article, available through Journal of Clinical Oncology.

ABCSG-8 Clinical Validation Study

Click here to access the ABCSG-8 clinical validation study article.

Analytical Validation Study

Click here to access the analytical validation study, available through BMC Cancer.

 

Information contained within these publications include information related to FDA-cleared products but is not consistent with the FDA-cleared Package Insert. Please refer to the FDA-cleared Package Insert for product information.

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy.

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.